LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
ChartMill assigns a Buy % Consensus number of 47% to LYEL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.04. This target is 114.74% above the current price.
LYEL was analyzed by 9 analysts. The buy percentage consensus is at 47. So analysts seem to be rather neutral about LYEL.
In the last month the buy percentage fell by 31 points. So the trust of analysts is decreasing.
LYEL was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-30 | B of A Securities | Downgrade | Buy -> Underperform |
| 2024-10-28 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-06-27 | B of A Securities | Maintains | Buy -> Buy |
| 2024-06-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-05-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-02 | HC Wainwright & Co. | Maintains | Buy |
| 2023-01-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-11-14 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-11-11 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-17 | HC Wainwright & Co. | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-01-06 | Morgan Stanley | Maintains | Overweight |
| 2021-07-12 | JP Morgan | Initiate | Overweight |
| 2021-07-12 | Goldman Sachs | Initiate | Buy |
| 2021-07-12 | B of A Securities | Initiate | Buy |
| 2021-07-12 | Morgan Stanley | Initiate | Overweight |